An interventional study of Intermittent Theta Burst Stimulation and Sham Intermittent Theta Burst Stimulation in Ischemic Stroke and Upper Limb Motor Impairment, sponsored by Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine. Not yet recruiting at 1 site in Russia. Open to participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Ischemic Stroke with a site in Russia — 13 open to participants now, 13 under way, 2 of them phase 3. Ischemic Stroke · Russia.
Among the 17 studies in Ischemic Stroke with a site in Russia, this one is one of 4 that started in 2026, is one of 4 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 13th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →13 of the 17 studies in Ischemic Stroke with a site in Russia are open now. Recruiting first, the newest first:
Supergene, LLC · Sites in Russia
Ages 18+
Pharmasoft · Sites in Russia
Ages 18–90 · Healthy volunteers
Tatchempharmpreparaty, JSC · Sites in Russia
Ages 35–80
Pirogov Russian National Research Medical University · Sites in Russia
Ages 40–80
POLYSAN Scientific & Technological Pharmaceutical Company · Sites in Russia
Ages 18+
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 40 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is close to the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 120 across the 9 interventional studies, 448 across the 8 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine has 2 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
6 of the studies in Ischemic Stroke with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07912151Samara State Medical UniversityDynamic Stabilometry Combined With Transcranial Direct Current Stimulation for Balance and Motor Recovery After Ischemic Stroke | 2026-12-28 |
| NCT06175715Pirogov Russian National Research Medical UniversityGeneral Versus Regional Anesthesia for Carotid Endarterectomy at Acute Ischemic Stroke Trial | 2026-12-31 |
| NCT07520630Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports MedicineNeurophysiological Markers for Prediction of Rehabilitation Outcomes After Ischemic Stroke | 2027-03 |
| NCT07575984PharmasoftMexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke | 2027-04 |
| NCT07083986Pirogov Russian National Research Medical UniversityCarotid Endarterectomy Versus Stenting in Patients With Acute Stage of Ischemic Stroke. | 2027-05-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 17 studies in Ischemic Stroke with a site in Russia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this randomized controlled study is to develop and validate an integrated neurophysiological model for predicting rehabilitation potential in patients with ischemic stroke. The study focuses on identifying objective markers of brain activity associated with motor preparation and recovery.
The project includes two stages. First, healthy volunteers will participate in experimental motor and mental tasks to establish reference patterns of brain activity using electroencephalography and transcranial magnetic stimulation. These data will be used to define stable neurophysiological markers of motor network function.
In the second stage, patients in the acute and early recovery phases after ischemic stroke will be randomly assigned to receive either active intermittent theta-burst stimulation of the motor cortex or a sham procedure, in addition to standard rehabilitation. Brain activity and clinical motor function will be assessed before and after the intervention.
The study aims to determine which neurophysiological measures are sensitive to neuromodulation and are associated with clinical improvement, in order to construct a predictive model of rehabilitation outcome.
Participants will [describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items].
Stroke remains a leading cause of long-term disability worldwide. Motor recovery after ischemic stroke is highly variable, and currently available clinical scales provide limited ability to predict rehabilitation potential at the individual level. There is a need for objective, neurophysiologically grounded biomarkers that reflect motor network integrity, cortical excitability, and adaptive neuroplasticity.
The present study aims to develop and validate an integrated neurophysiological model for predicting rehabilitation outcomes in patients with ischemic stroke. The model is based on a multimodal assessment combining electroencephalography (EEG), performed during standardized ecologically valid motor and mental paradigms, and diagnostic transcranial magnetic stimulation (TMS).
The project consists of two interconnected stages.
Stage 1 (Experimental Reference Phase in Healthy Volunteers):
Healthy adult participants will perform standardized motor execution and motor imagery paradigms under EEG and surface electromyography monitoring. Cortical excitability will be assessed using diagnostic TMS. This phase is designed to identify stable neurophysiological patterns associated with motor preparation and execution, including movement-related cortical potentials, sensorimotor rhythm modulation, and measures of functional connectivity. These data will serve as reference patterns to define candidate biomarkers for subsequent clinical testing.
Stage 2 (Randomized Controlled Clinical Phase):
Patients in the acute and early recovery stages following first-ever ischemic stroke will be randomly assigned to receive either active intermittent theta-burst stimulation (iTBS) of the ipsilesional primary motor cortex or sham stimulation, in addition to standard rehabilitation therapy. The intervention course will consist of multiple stimulation sessions delivered over a two-week period.
Neurophysiological assessments (EEG and diagnostic TMS) will be conducted before and after the intervention. Clinical motor and cognitive function will be evaluated using standardized scales at baseline and post-intervention time points.
The randomized design allows evaluation of the sensitivity of candidate neurophysiological markers to neuromodulatory intervention and their association with clinical recovery dynamics. By integrating electrophysiological measures of cortical excitability, motor network synchronization, and interregional connectivity with clinical outcomes, the study seeks to identify a minimal set of objective markers capable of predicting rehabilitation response.
The ultimate objective is to construct and statistically validate a predictive model of rehabilitation potential that may support individualized planning of post-stroke neurorehabilitation strategies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Experimental phase:
will include healthy volunteers without contradictions to TMS
Clinical phase:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Intermittent Theta Burst Stimulation
Device: Sham Intermittent Theta Burst Stimulation
Once a day, 10 days of Intermittent Theta-Burst Stimulation (iTBS) applied to ipsilesional primary motor cortex (M1).
Once a day, 10 days of Sham Theta-Burst Stimulation using placebo coil
Change in Muscle Strength Assessed by the Medical Research Council Scale (MRC)
Muscle strength of the affected upper limb assessed using the Medical Research Council (MRC) scale, ranging from 0 (no muscle contraction) to 5 (normal muscle strength). Higher scores indicate better motor function.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Change in Muscle Tone Assessed by the Modified Ashworth Scale (MAS)
Muscle tone of the affected upper limb assessed using the Modified Ashworth Scale (MAS), which ranges from 0 (no increase in muscle tone) to 4 (Affected part(s) rigid in flexion or extension). Higher scores indicate greater spasticity.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Change in Upper Limb Motor Function (Fugl-Meyer Assessment - Upper Extremity)
Upper limb motor impairment assessed using the Fugl-Meyer Assessment for the Upper Extremity (FMA-UE). Scores range from 0 to 66, with higher scores indicating better upper limb motor function.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Change in Cognitive Function Assessed by Montreal Cognitive Assessment (MoCA)
Global cognitive function assessed using the Montreal Cognitive Assessment (MoCA), a 30-point cognitive screening tool. Scores range from 0 to 30, with higher scores indicating better cognitive function.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Change in Modified Rankin Scale (mRS) score
Global disability assessed using the modified Rankin Scale (mRS). Scores range from 0 to 6, higher scores indicate greater disability.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Change in Action Research Arm Test (ARAT) score
Upper limb functional capacity assessed using the Action Research Arm Test (ARAT). Scores range from 0 to 57, with higher scores indicating better upper limb function.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Change in Nine-Hole Peg Test (NHPT) completion time
Manual dexterity assessed using the Nine-Hole Peg Test (NHPT), a timed test of fine hand dexterity. Completion time is recorded in seconds; lower times indicate better manual dexterity.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Change in Frenchay Arm Test (FAT) score
Upper limb functional performance in daily activities assessed using the Frenchay Arm Test (FAT), a 5-item test of arm and hand function after stroke. Scores range from 0 to 5, with higher scores indicating better upper limb function.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Change in Event-Related Desynchronization (ERD) of Sensorimotor Rhythm
Event-related desynchronization (ERD) of sensorimotor rhythm in the 8-30 Hz frequency range measured using scalp electroencephalography during motor execution and motor imagery tasks. ERD is expressed as percentage decrease in band power relative to a pre-movement baseline, reflecting cortical activation.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Change in Event-Related Synchronization (ERS) of Sensorimotor Rhythm
Event-related synchronization (ERS) of sensorimotor rhythm in the 8-30 Hz frequency range measured using scalp electroencephalography during motor execution and motor imagery tasks. ERS is expressed as percentage increase in band power relative to a pre-movement baseline, reflecting post-movement cortical synchronization.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Change in Movement-Related Cortical Potential (MRCP) Amplitude
Amplitude of movement-related cortical potential (MRCP) recorded using scalp electroencephalography during motor execution and motor imagery tasks. MRCP amplitude is measured in microvolts (µV) relative to a pre-movement baseline and reflects cortical activity associated with motor preparation.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Change in Movement-Related Cortical Potential (MRCP) Latency
Latency of movement-related cortical potentials (MRCPs) recorded using scalp electroencephalography during motor execution and motor imagery tasks. MRCP latency is defined as the time interval in milliseconds (ms) between MRCP onset and movement onset.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Motor Evoked Potential (MEP) Amplitude
Peak-to-peak amplitude of motor evoked potentials (MEPs) recorded at rest from the target upper limb muscle using surface electromyography following single-pulse transcranial magnetic stimulation of the primary motor cortex. MEP amplitude is measured in millivolts (mV) and reflects corticospinal excitability.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Resting Motor Threshold (RMT)
Resting motor threshold (RMT) defined as the minimum stimulator intensity required to evoke motor evoked potentials (MEPs) in the target muscle in at least 50% of trials with the muscle at rest. The threshold is expressed as a percentage of maximal stimulator output (% MSO).
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Change in Weighted Phase Lag Index (wPLI) in the Sensorimotor Network
Functional connectivity within the sensorimotor network assessed using the weighted phase lag index (wPLI), a phase-based connectivity measure derived from electroencephalography signals during motor execution and motor imagery tasks. wPLI values range from 0 to 1, with higher values indicating stronger phase synchronization between cortical regions.
Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Mar 2027, 10 months later.
Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 10 months is below that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine